BioCentury | Apr 13, 2021
Product Development

AACR Quick Takes: Guardant, Gracell, iTeos, Zentalis, ImCheck, PureTech

...81.5% positive percent agreement and 100% negative percent agreement with a tumor tissue-based test from Qiagen N.V....
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

...market, with a market cap above $6 billion.Qiagen N.V....
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

...molecular diagnostics, is a veteran of Novartis AG (NYSE:NVS; SIX:NOVN), Myriad Genetics Inc. (NASDAQ:MYGN) and Qiagen N.V....
BioCentury | Nov 12, 2020
Product Development

Russian vaccine data add to expectations for COVID-19 vaccine efficacy set by BioNTech, Pfizer; Moderna readout coming

...yield enough antibodies to start Phase I testing.Qiagen...
...antibody and antigen tests to be run simultaneously.Qiagen...
...Research Institute of Epidemiology and Microbiology Pfizer Inc. Ellume Ltd. Qiagen N.V. Moderna...
BioCentury | Aug 22, 2020
Management Tracks

Qiagen chairman steps down, plus changes at Sanifit and Xeris

...By Elizabeth s. eaton, Staff Writer Qiagen N.V. (NYSE:QGEN; Xetra:QIA) Chairman Håkan Björklund has stepped down, a week...
...company Xeris Pharmaceuticals Inc. (NASDAQ:XERS) has promoted COO John Shannon to president and COO. Elizabeth S. Eaton Qiagen N.V. Sanifit...
BioCentury | Aug 14, 2020
Finance

Aug. 13 Quick Takes: Qiagen shareholders opt for independence; plus IPO terms from Inhibrx, Harmony and more from Biohaven-Royalty, Scioto, Bodyport, immunoSCAPE

...By Biocentury staff Qiagen to remain independentQiagen N.V. (NYSE:QGEN; Xetra:QIA) said it terminated its agreement to...
...acquired by Thermo Fisher Scientific Inc. (NYSE:TMO) after only 47% of shares were tendered by Qiagen...
...diagnostics company for €39 ($43.33) per share, or about $11.5 billion (see “Thermo Fisher Takes out Qiagen”).Inhibrx, Harmony near...
BioCentury | Jun 26, 2020
Politics, Policy & Law

Illumina, BGI litigation not yet at risk of getting drawn into U.S.-China dispute

...compare the nature of the lawsuits between Illumina and BGI and that between Illumina and Qiagen...
...BGI. Since 2012, Illumina has had an ongoing patent dispute with its largest European competitor, Qiagen N.V....
...compare the nature of the lawsuits between Illumina and BGI and that between Illumina and Qiagen...
BioCentury | Mar 31, 2020
Product Development

COVID-19 roundup: Qiagen, BD-BioMedomics, Rendu, Vaxart, Cobra, GigaGen, Houston Methodist, Anaqua-WideTrial

...FDA’s emergency use authorization for a Qiagen test Tuesday comes amid a flurry of advancements in...
...GigaGen’s unveiling of a polyclonal antibody program derived from convalescent COVID-19 patients. The test from Qiagen N.V....
...choice. Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Sandi Wong, Assistant Editor Qiagen N.V. Becton...
BioCentury | Mar 31, 2020
Finance

With new $450M fund, Gilde is latest European firm to aim for bigger holdings in earlier-stage investments

...for €360 million in milestones. It also invested in Stat-Dx Life S.L., a diagnostics company Qiagen N.V....
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...become the permanent CEO after serving on an interim basis since October. Bernard, who joined Qiagen...
...to provide diagnostic testing during the COVID-19 pandemic. Thermo Fisher Scientific Inc. (NYSE:TMO) is acquiring Qiagen...
...is retiring April 30. Reali was president and CEO of Clinical Innovations LLC. Robin Sawka, BioCentury Staff Qiagen N.V. CytomX...
Items per page:
1 - 10 of 750
BioCentury | Apr 13, 2021
Product Development

AACR Quick Takes: Guardant, Gracell, iTeos, Zentalis, ImCheck, PureTech

...81.5% positive percent agreement and 100% negative percent agreement with a tumor tissue-based test from Qiagen N.V....
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

...market, with a market cap above $6 billion.Qiagen N.V....
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

...molecular diagnostics, is a veteran of Novartis AG (NYSE:NVS; SIX:NOVN), Myriad Genetics Inc. (NASDAQ:MYGN) and Qiagen N.V....
BioCentury | Nov 12, 2020
Product Development

Russian vaccine data add to expectations for COVID-19 vaccine efficacy set by BioNTech, Pfizer; Moderna readout coming

...yield enough antibodies to start Phase I testing.Qiagen...
...antibody and antigen tests to be run simultaneously.Qiagen...
...Research Institute of Epidemiology and Microbiology Pfizer Inc. Ellume Ltd. Qiagen N.V. Moderna...
BioCentury | Aug 22, 2020
Management Tracks

Qiagen chairman steps down, plus changes at Sanifit and Xeris

...By Elizabeth s. eaton, Staff Writer Qiagen N.V. (NYSE:QGEN; Xetra:QIA) Chairman Håkan Björklund has stepped down, a week...
...company Xeris Pharmaceuticals Inc. (NASDAQ:XERS) has promoted COO John Shannon to president and COO. Elizabeth S. Eaton Qiagen N.V. Sanifit...
BioCentury | Aug 14, 2020
Finance

Aug. 13 Quick Takes: Qiagen shareholders opt for independence; plus IPO terms from Inhibrx, Harmony and more from Biohaven-Royalty, Scioto, Bodyport, immunoSCAPE

...By Biocentury staff Qiagen to remain independentQiagen N.V. (NYSE:QGEN; Xetra:QIA) said it terminated its agreement to...
...acquired by Thermo Fisher Scientific Inc. (NYSE:TMO) after only 47% of shares were tendered by Qiagen...
...diagnostics company for €39 ($43.33) per share, or about $11.5 billion (see “Thermo Fisher Takes out Qiagen”).Inhibrx, Harmony near...
BioCentury | Jun 26, 2020
Politics, Policy & Law

Illumina, BGI litigation not yet at risk of getting drawn into U.S.-China dispute

...compare the nature of the lawsuits between Illumina and BGI and that between Illumina and Qiagen...
...BGI. Since 2012, Illumina has had an ongoing patent dispute with its largest European competitor, Qiagen N.V....
...compare the nature of the lawsuits between Illumina and BGI and that between Illumina and Qiagen...
BioCentury | Mar 31, 2020
Product Development

COVID-19 roundup: Qiagen, BD-BioMedomics, Rendu, Vaxart, Cobra, GigaGen, Houston Methodist, Anaqua-WideTrial

...FDA’s emergency use authorization for a Qiagen test Tuesday comes amid a flurry of advancements in...
...GigaGen’s unveiling of a polyclonal antibody program derived from convalescent COVID-19 patients. The test from Qiagen N.V....
...choice. Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Sandi Wong, Assistant Editor Qiagen N.V. Becton...
BioCentury | Mar 31, 2020
Finance

With new $450M fund, Gilde is latest European firm to aim for bigger holdings in earlier-stage investments

...for €360 million in milestones. It also invested in Stat-Dx Life S.L., a diagnostics company Qiagen N.V....
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...become the permanent CEO after serving on an interim basis since October. Bernard, who joined Qiagen...
...to provide diagnostic testing during the COVID-19 pandemic. Thermo Fisher Scientific Inc. (NYSE:TMO) is acquiring Qiagen...
...is retiring April 30. Reali was president and CEO of Clinical Innovations LLC. Robin Sawka, BioCentury Staff Qiagen N.V. CytomX...
Items per page:
1 - 10 of 750